Phaseline

Targets › GNRH1

GNRH1 (Progonadoliberin-1): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 3 Phase 3; Other, Oncology, Metabolic and endocrine; next expected readout Jan 2027.

[Gonadoliberin-1]: Hypothalamic decapeptide hormone that functions as the master regulator of the hypothalamic-pituitary-gonadal axis. Released in a pulsatile manner from hypothalamic neuron terminals into the hypophyseal portal circulation, it acts on pituitary gonadotrope cells by binding to and activating its cognate G protein-coupled receptor GNRHR, thereby stimulating the synthesis and secretion of the…. (UniProt, P01148)

Open in Phaseline: the race on GNRH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TolmarTOL2506
GnRH receptor agonist for ovarian suppression
GNRH1Phase 3Breast CancerJan 2027
Assistance Publique - Hôpitaux de ParisNafarelin
GnRH agonist for luteal phase support
GNRH1Phase 3In Vitro FertilizationSep 2027
Debiopharm InternationalDebio 4326
GnRH receptor agonist
GNRH1Phase 3Central Precocious PubertyFeb 2028

Conditions

In Vitro Fertilization (1) Breast Cancer (1) Central Precocious Puberty (1)

Modalities

small molecule (2), protein or peptide (1)

Companies

Assistance Publique - Hôpitaux de Paris (1) Tolmar (1) Debiopharm International (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.